Scientists uncover new hiding spot for HIV in marrow
Decision brief
Answer first · skim in under a minute
A team led by virologist Kathleen Collins at the University of Michigan has discovered that HIV can hide inside bone marrow cells, revealing a previously unknown reservoir. This finding challenges current cure strategies and opens new avenues for therapeutic targeting.
Scientists uncover new hiding spot for HIV in bone marrow: University of Michigan research led by Kathleen Collins established that HIV can persist in hematopoietic progenitors, expanding the map of latent reservoirs that antiretroviral therapy alone does not clear and that cure programs must address.
Contents10 sections
Key Takeaways
- A 2010 Nature Medicine study from the Collins lab showed HIV-1 can infect multipotent progenitor cells, cause cell death, and establish latent cellular reservoirs in bone marrow.
- A 2017 PLOS Pathogens follow-on detected HIV provirus in HSPCs from optimally treated donors, including CCR5- and CXCR4-tropic genomes in non-stem progenitors that persisted for years.
- In that cohort, 24 of 41 evaluable donors (59%) had detectable HSPC-associated provirus, with a mean frequency of about 2.4 copies per million cells.
- NIH-summarized shock-and-kill work shows latency reversal can reach bone marrow in animal models, but human clearance of marrow reservoirs remains unproven.
What did University of Michigan researchers show about HIV in bone marrow?
The Collins group demonstrated that bone marrow is not an HIV-free sanctuary. In Nature Medicine (2010), Carter, Collins, and colleagues reported that HIV-1 infects multipotent progenitor cells, can kill infected cells, and can establish latent reservoirs that current antiretrovirals do not eradicate.
That finding reframed cure biology for industry teams: latent HIV is not limited to circulating memory CD4+ T cells. Marrow progenitors that seed blood lineages can archive provirus and, after differentiation or reactivation, contribute to rebound if therapy stops.
How large is the hematopoietic progenitor reservoir in treated people?
In PLOS Pathogens (2017), Sebastian, Collins, and colleagues analyzed bone marrow from 47 HIV-infected donors on therapy with undetectable viral loads for at least six months. After purity filters, 41 donors were evaluable.
- 59% of evaluable donors (24 of 41) had detectable HIV provirus in HSPCs.
- Mean provirus frequency was about 2.4 copies per million HSPCs (range spanned less than 1 per 1.3 million to 18 per million).
- Near full-length amplicon analysis suggested roughly 30% of assayed HSPC proviral genomes were likely intact and potentially functional.
- Both CCR5-tropic and CXCR4-tropic env genotypes were recovered from HSPCs, including from stem-cell-depleted restricted progenitor sorts.
Those numbers matter for competitive intelligence: any claim that a cure candidate “clears reservoirs” is incomplete if marrow HSPCs are not sampled.
How does this affect shock-and-kill and long-acting HIV R&D?
Shock-and-kill aims to reverse latency so immune effectors or cytolytic drugs can eliminate previously silent cells. An NIH Research Matters summary (2020) of companion Nature studies described latency reversal with AZD5582 in humanized mice, with viral reproduction detected in bone marrow among other tissues, and reactivation in about half of treated SIV-infected macaques.
For developers of latency-reversing agents, broadly neutralizing antibodies, and long-acting injectables, the implication is pharmacokinetic as much as virologic. Teams should ask whether candidate exposures reach marrow stroma and whether reactivation assays include HSPC models, not only peripheral blood mononuclear cells. Coverage of related antiviral franchises, including Gilead Hepcludex FDA approval and lenacapavir PURPOSE 1 prevention data, sits alongside this reservoir science for pipeline watchers.
Which cell types in marrow matter most for product strategy?
The 2010 work centered on multipotent progenitors as both infection targets and latent reservoirs. The 2017 paper extended that map: CD4-high HSPC subsets, including multipotent progenitors, were preferentially targeted in vitro, and restricted non-stem progenitors harbored CCR5-tropic provirus for years in treated people.
That distinction changes target-product profiles. A modality aimed only at long-lived stem cells may miss restricted progenitors that still persist. Conversely, agents that require active viral protein expression will fail against deeply silenced HSPC provirus unless paired with a marrow-competent latency reversal step.
What should competitive intelligence teams watch next?
Watch for clinical protocols that add bone marrow HSPC sampling to analytic treatment interruption studies, patent filings on marrow-homing delivery of latency-reversing agents, and combination regimens that pair shock agents with immune clearance. Also track whether long-acting regimens such as Merck’s IDVYNSO (doravirine/islatravir) publish tissue pharmacokinetic data that include marrow, not only plasma troughs.
WHO continues to frame lifelong antiretroviral therapy as the global standard while cure research remains early; that gap between durable suppression and sterilizing or functional cure is exactly where marrow reservoir biology sits.
What remains unproven
Collins-lab papers establish infection, tropism breadth, and multi-year persistence of HIV genomes in marrow HSPCs. They do not show that any approved drug, late-stage LRA, or gene-editing approach clears that compartment in humans. Animal latency-reversal signals in marrow are proof-of-mechanism, not clinical cure. Claims that a June 2026 news cycle newly “discovered” this hiding spot overstate the timeline; the primary literature dates to 2010 and 2017, with later NIH-summarized shock-and-kill work reinforcing why marrow still matters.
Related NovaPharma coverage
- Gilead Hepcludex FDA approval and hepatitis D implications
- Lenacapavir PURPOSE 1: 100% HIV prevention readout
- FDA approves Merck IDVYNSO HIV treatment
Frequently Asked Questions
Where does HIV hide in bone marrow?
University of Michigan studies led by Kathleen Collins show HIV can persist as latent provirus in hematopoietic stem and progenitor cells (HSPCs) in bone marrow, including non-stem restricted progenitors that remain detectable after years of effective antiretroviral therapy.
Why does a bone marrow reservoir matter for HIV cure programs?
Cure strategies such as shock-and-kill mainly target latent virus in resting CD4+ T cells and lymphoid tissues. A durable marrow HSPC reservoir means latency-reversing agents, immune effectors, and long-acting antiretrovirals also need adequate activity and exposure in that compartment.
What remains unproven about clearing HIV from marrow?
Primary papers establish infection and persistence of provirus in HSPCs; they do not prove that any licensed or late-stage latency-reversing regimen clears marrow reservoirs in people. Human cure trials still need marrow-focused pharmacodynamic and reservoir assays.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
